GlassScriptPhysician profile
James P Adlam
NPI 1033641949
$14,767.21
in general payments reported to CMS, 2019-2025
19 companies · $490 in 2025
The $490 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $113 · 2021: $2,994 · 2022: $745 · 2023: $10K · 2024: $400 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $8,500 · Food and Beverage: $2,251 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $8,500.00 |
| Food and Beverage | $2,250.69 |
| Education | $164.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,145.40 | 2021-2025 | Onyx Frontier, Corevalve Evolut R |
| Abbott Laboratories | $4,732.87 | 2023-2024 | Cardiomems, Diamondback Coronary, Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $842.28 | 2021-2023 | Watchman Access System, Avvigo Guidance System |
| Astrazeneca Pharmaceuticals LP | $443.01 | 2020-2024 | Brilinta |
| Biotronik INC. | $242.76 | 2022-2024 | Orsiro Mission |
| Abiomed | $230.85 | 2023-2024 | Impella |
| Philips North America LLC | $198.37 | 2022-2025 | Coronary Other |
| Teleflex LLC | $165.46 | 2023 | Guideliner |
| E.R. Squibb & Sons, L.L.C. | $147.53 | 2023-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $106.09 | 2023 | Opsumit |
| Cordis US Corp. | $102.06 | 2023 | Mynx Control |
| Edwards Lifesciences Corporation | $92.32 | 2021 | |
| Chiesi USA, INC. | $72.00 | 2023 | Kengreal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.51 | 2025 | Jardiance |
| Amgen INC. | $57.69 | 2025 | Repatha |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $48.00 | 2023 | Indigo System |
| Pfizer INC. | $29.62 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.71 | 2025 | |
| Lantheus Medical Imaging, INC. | $22.68 | 2023 | Definity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Adlam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.